Last reviewed · How we verify
formoterol Turbuhaler
At a glance
| Generic name | formoterol Turbuhaler |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (PHASE3)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients (PHASE3)
- Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10) (NA)
- Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation (PHASE3)
- Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair) (NA)
- As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period (PHASE3)
- Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- formoterol Turbuhaler CI brief — competitive landscape report
- formoterol Turbuhaler updates RSS · CI watch RSS
- AstraZeneca portfolio CI